Exendin-4-encapsulated dissolving microneedle arrays for efficient treatment of type 2 diabetes

Shayan Fakhraei Lahiji, Yoojung Jang, Inyoung Huh, Huisuk Yang, Mingyu Jang, Hyungil Jung

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Dissolving microneedles (DMNs) are microscopic needles capable of delivering encapsulated compounds and releasing them into the skin in a minimally invasive manner. Most studies indicate that encapsulating therapeutics in DMNs is an efficacious approach; however, the importance of evaluating the activity of encapsulated compounds, during the fabrication process, has not been examined in detail. Conducting an analysis of thermal, chemical, and physical stress factors, including temperature, pH, and the interaction of the polymer and therapeutics mixture during preparation, is essential for retaining the activity of encapsulated therapeutics during and after fabrication. Here, we optimised the thermal, chemical, and physical parameters for the fabrication of exendin-4 (Ex-4)-encapsulated DMNs (Ex-4 DMNs). Ex-4, a peptide agonist of glucagon-like peptide (GLP) receptor, is used for glycaemic control in patients with type 2 diabetes. Our findings indicate that optimising the parameters involved in DMN fabrication retained the activity of Ex-4 by up to 98.3 ± 1.5%. Ex-4 DMNs reduced the blood-glucose level in diabetic mice with efficiency similar to that of a subcutaneous injection. We believe that this study paves way for the commercialisation of an efficient and minimally invasive treatment for patients with type 2 diabetes.

Original languageEnglish
Article number1170
JournalScientific reports
Volume8
Issue number1
DOIs
Publication statusPublished - 2018 Dec 1

Fingerprint

Type 2 Diabetes Mellitus
Hot Temperature
Subcutaneous Injections
Therapeutics
Needles
Blood Glucose
Polymers
Skin
Peptides
Temperature
exenatide

All Science Journal Classification (ASJC) codes

  • General

Cite this

Fakhraei Lahiji, Shayan ; Jang, Yoojung ; Huh, Inyoung ; Yang, Huisuk ; Jang, Mingyu ; Jung, Hyungil. / Exendin-4-encapsulated dissolving microneedle arrays for efficient treatment of type 2 diabetes. In: Scientific reports. 2018 ; Vol. 8, No. 1.
@article{208cef9fc3024a9c8e4178fb22b9039b,
title = "Exendin-4-encapsulated dissolving microneedle arrays for efficient treatment of type 2 diabetes",
abstract = "Dissolving microneedles (DMNs) are microscopic needles capable of delivering encapsulated compounds and releasing them into the skin in a minimally invasive manner. Most studies indicate that encapsulating therapeutics in DMNs is an efficacious approach; however, the importance of evaluating the activity of encapsulated compounds, during the fabrication process, has not been examined in detail. Conducting an analysis of thermal, chemical, and physical stress factors, including temperature, pH, and the interaction of the polymer and therapeutics mixture during preparation, is essential for retaining the activity of encapsulated therapeutics during and after fabrication. Here, we optimised the thermal, chemical, and physical parameters for the fabrication of exendin-4 (Ex-4)-encapsulated DMNs (Ex-4 DMNs). Ex-4, a peptide agonist of glucagon-like peptide (GLP) receptor, is used for glycaemic control in patients with type 2 diabetes. Our findings indicate that optimising the parameters involved in DMN fabrication retained the activity of Ex-4 by up to 98.3 ± 1.5{\%}. Ex-4 DMNs reduced the blood-glucose level in diabetic mice with efficiency similar to that of a subcutaneous injection. We believe that this study paves way for the commercialisation of an efficient and minimally invasive treatment for patients with type 2 diabetes.",
author = "{Fakhraei Lahiji}, Shayan and Yoojung Jang and Inyoung Huh and Huisuk Yang and Mingyu Jang and Hyungil Jung",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-19789-x",
language = "English",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

Exendin-4-encapsulated dissolving microneedle arrays for efficient treatment of type 2 diabetes. / Fakhraei Lahiji, Shayan; Jang, Yoojung; Huh, Inyoung; Yang, Huisuk; Jang, Mingyu; Jung, Hyungil.

In: Scientific reports, Vol. 8, No. 1, 1170, 01.12.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Exendin-4-encapsulated dissolving microneedle arrays for efficient treatment of type 2 diabetes

AU - Fakhraei Lahiji, Shayan

AU - Jang, Yoojung

AU - Huh, Inyoung

AU - Yang, Huisuk

AU - Jang, Mingyu

AU - Jung, Hyungil

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Dissolving microneedles (DMNs) are microscopic needles capable of delivering encapsulated compounds and releasing them into the skin in a minimally invasive manner. Most studies indicate that encapsulating therapeutics in DMNs is an efficacious approach; however, the importance of evaluating the activity of encapsulated compounds, during the fabrication process, has not been examined in detail. Conducting an analysis of thermal, chemical, and physical stress factors, including temperature, pH, and the interaction of the polymer and therapeutics mixture during preparation, is essential for retaining the activity of encapsulated therapeutics during and after fabrication. Here, we optimised the thermal, chemical, and physical parameters for the fabrication of exendin-4 (Ex-4)-encapsulated DMNs (Ex-4 DMNs). Ex-4, a peptide agonist of glucagon-like peptide (GLP) receptor, is used for glycaemic control in patients with type 2 diabetes. Our findings indicate that optimising the parameters involved in DMN fabrication retained the activity of Ex-4 by up to 98.3 ± 1.5%. Ex-4 DMNs reduced the blood-glucose level in diabetic mice with efficiency similar to that of a subcutaneous injection. We believe that this study paves way for the commercialisation of an efficient and minimally invasive treatment for patients with type 2 diabetes.

AB - Dissolving microneedles (DMNs) are microscopic needles capable of delivering encapsulated compounds and releasing them into the skin in a minimally invasive manner. Most studies indicate that encapsulating therapeutics in DMNs is an efficacious approach; however, the importance of evaluating the activity of encapsulated compounds, during the fabrication process, has not been examined in detail. Conducting an analysis of thermal, chemical, and physical stress factors, including temperature, pH, and the interaction of the polymer and therapeutics mixture during preparation, is essential for retaining the activity of encapsulated therapeutics during and after fabrication. Here, we optimised the thermal, chemical, and physical parameters for the fabrication of exendin-4 (Ex-4)-encapsulated DMNs (Ex-4 DMNs). Ex-4, a peptide agonist of glucagon-like peptide (GLP) receptor, is used for glycaemic control in patients with type 2 diabetes. Our findings indicate that optimising the parameters involved in DMN fabrication retained the activity of Ex-4 by up to 98.3 ± 1.5%. Ex-4 DMNs reduced the blood-glucose level in diabetic mice with efficiency similar to that of a subcutaneous injection. We believe that this study paves way for the commercialisation of an efficient and minimally invasive treatment for patients with type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=85040774997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040774997&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-19789-x

DO - 10.1038/s41598-018-19789-x

M3 - Article

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 1170

ER -